Alternative Data for Insulet
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 453 | Sign up | Sign up | Sign up |
| Sentiment | 66 | Sign up | Sign up | Sign up |
| Webpage traffic | 84,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3,490 | Sign up | Sign up | Sign up |
| Facebook Followers | 98,300 | Sign up | Sign up | Sign up |
| Instagram Followers | 65,679 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 24 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,916 | Sign up | Sign up | Sign up |
| X Followers | 8,132 | Sign up | Sign up | Sign up |
| X Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 76 | Sign up | Sign up | Sign up |
| Linkedin Employees | 4,848 | Sign up | Sign up | Sign up |
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
| Price | $236.07 |
| Target Price | Sign up |
| Volume | 928,165 |
| Market Cap | $16.8B |
| Year Range | $236.07 - $352.82 |
| Dividend Yield | 0% |
| PE Ratio | 68.46 |
| Analyst Rating | 88% buy |
| Industry | Medical Devices |
In the news
Truist Lowers its Price Target on Insulet Corporation (PODD) to $360 and Maintains a Buy RatingFebruary 26 - Yahoo Entertainment |
|
 |
Insulet Corp (NASDAQ:PODD): A High-Growth Stock Forming a Technical BaseFebruary 24 - ChartMill |
 |
O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD)February 23 - Yahoo |
Insulet shares are trading higher after a Form 4 filing showed its CEO purchased 4,300 shares at an average price of $239.35.February 22 - Benzinga |
|
 |
Positive Signal: Ashley McEvoy Shows Faith, Buying $1.03M In Insulet StockFebruary 22 - Benzinga |
 |
Insulet price target lowered by $30 at Evercore ISIFebruary 19 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 784M | 215M | 569M | 102M | 146M | 1.550 |
| Q3 '25 | 706M | 196M | 510M | 88M | 160M | 1.240 |
| Q2 '25 | 649M | 197M | 452M | 23M | 70M | 1.170 |
| Q1 '25 | 569M | 160M | 409M | 35M | 79M | 1.020 |
| Q4 '24 | 598M | 167M | 431M | 101M | 142M | 1.150 |
Insider Transactions View All
| MINOGUE MICHAEL R filed to buy 17,483 shares at $246.2. February 26 '26 |
| McEvoy Ashley filed to buy 13,916 shares at $239.4. February 23 '26 |
| Frederick Wayne A.I. filed to sell 2,158 shares at $293.1. December 16 '25 |
| STONESIFER TIMOTHY C. filed to buy 4,591 shares at $311.7. December 8 '25 |
| Cousin Laetitia filed to sell 3,890 shares at $348.8. September 9 '25 |
Similar companies
Read more about Insulet (PODD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Insulet
The Market Cap of Insulet is $16.8B.
As of today, Insulet's PE (Price to Earnings) ratio is 68.46.
Currently, the price of one share of Insulet stock is $236.07.
The PODD stock price chart above provides a comprehensive visual representation of Insulet's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Insulet shares. Our platform offers an up-to-date PODD stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Insulet (PODD) does not offer dividends to its shareholders. Investors interested in Insulet should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Insulet are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
